Manchester University NHS Foundation Trust (MFT)

Manchester University NHS Foundation Trust (MFT) was established on October 1 2017, following the merger of Central Manchester University Hospitals NHS Foundation Trust (CMFT) and the University Hospital of South Manchester NHS Foundation Trust (UHSM).

Employing over 20,000 staff, MFT provides hospital care and a wide range of specialist and nationally commissioned services for people living in the City of Manchester, Trafford and beyond. Throughout the north west, the trust has the largest number of undergraduates and clinical staff in training and holds the biggest research portfolio.

The trust includes all the hospitals that were previously part of CMFT and UHSM: Manchester Royal Eye Hospital, Manchester Royal Infirmary, Royal Manchester Children's Hospital, Saint Mary's Hospital, The University Dental Hospital, Altrincham Hospital, Trafford General Hospital, Wythenshawe Hospital, Withington Community Hospital, plus Community Services. North Manchester General Hospital (which is currently part of The Pennine Acute Hospitals NHS Trust) will join MFT in the second half of 2019/2020, subject to due diligence, agreement of financial plans and approval of business cases.   


MFT’s secondary care and specialist services are delivered through Manchester Royal Infirmary, Manchester Royal Eye Hospital, Royal Manchester Children’s Hospital, Saint Mary’s Hospital, The University Dental Hospital, Manchester, Trafford Hospitals (Trafford and Altrincham Hospital) and Wythenshawe Hospital.

The Trust also manages 45 community services including adult services e.g. district nursing, continence and podiatry for the central Manchester area, along with children's services, contraception and sexual health, community dentistry, and learning disabilities services for the whole of the city.

Royal Manchester Children’s Hospital is the UK’s largest children’s hospital. It has the largest specialist paediatric burns unit in the country, the first of its kind in the UK when it opened in 1953. The paediatric intensive care unit (PICU) is the largest general PICU in the UK.

Manchester Royal Infirmary provides services to the local community and a wide range of specialist services to patients from across the north west. Amongst many milestones, they have performed over 1,000 cochlear implants and 4,000 kidney transplants. They provide specialist services to adults with congenital heart disease, and numerous other specialist medical and surgical services.

The Manchester Royal Eye Hospital is one is one of only two specialist eye hospitals in the UK, with a full range of specialist services for patients with eye diseases. It is one of only two centres in the UK to take part in the bionic eye trial, in which 32 patients worldwide participated.

Saint Mary’s Hospital now delivers over 7,000 babies each year. The hospital has the only genetics service and the only surgical centre for new-born babies in the region. It was the first NHS IVF unit in the country. The Saint Mary’s Centre was the first sexual assault referral centre to be launched in the country.

Wythenshawe Hospital is a major acute teaching hospital and is recognised as a centre of clinical excellence, providing district general hospital services and specialist tertiary services to its local community. The hospital’s fields of specialist expertise include cardiology and cardiothoracic surgery, heart and lung transplantation, respiratory conditions, burns and plastics, cancer and breast care services.

In December 2011, MFT was accredited NHS Litigation Authority (NHSLA) Level 3 for all their services.

Research excellence

MFT’s Research and Innovation Division drives continuous improvement in patient care through clinical research, working with industry and strategic partners.

With a current annual turnover of £56million, the Division supports 300 principal investigators, 150 research nurses and midwives and 70 trial coordinator staff, to deliver around 500 studies a year. It also provides access to clinical expertise to inform understanding of market need and develop/trial new diagnostics and devices.

MFT also hosts a range of National Institute for Health Research (NIHR) infrastructure:

  • The NIHR Manchester Biomedical Research Centre transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients in the areas of musculoskeletal disease, hearing health, respiratory disease, dermatology and cancer.
  • The NIHR Manchester Clinical Research Facility brings together four dedicated experimental medicine research units across Greater Manchester, to deliver complex high-quality experimental studies to time and target.
  • The NIHR Clinical Research Network: Greater Manchester supports the delivery of health research across Greater Manchester, East Cheshire and East Lancashire, across 14 NHS Trusts, 11 CCGs and more than 500 GP practices.

Working across the wider Greater Manchester region, MFT hosts Health Innovation Manchester, an academic health science and innovation system transforming the health and wellbeing of Greater Manchester’s 2.8 million citizens.

By harnessing the skills of the regions world-leading researchers, Health Innovation Manchester fosters partnerships with industry to support the NHS and social care providers. It also promotes health innovation through digital technology, changes to practice or optimising medication.

The Trust has established a Diagnostic and Technology Accelerator, a catalyst for evidence generation for commercial in vitro diagnostics and medical devices. Through partnerships with numerous national networks, the team can rapidly prioritise, design and deliver both small- and large-scale clinical evaluations of new technologies.

After launching Citylabs 1.0 in 2014, MFT is working with Manchester Science Partnerships to develop Citylabs 2.0 & 3.0 which will provide 300,000ft² of commercial office and lab space for life science and digital companies. The campus will become a hub for precision medicine and data analytical businesses to accelerate innovation in these sectors and adopt them within patient care at pace and scale through collaboration. 

Chief Executive: Sir Michael Deegan CBE

© 2019 — The Shelford Group

Keep up to date

Follow The Shelford Group on Twitter and our RSS Feed.

If you would like more information about the Shelford Group or to get in touch, please click here